Malte Peters - 08 Jan 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: President & CEO, Director
Issuer ticker: TNGX
Reported as of: 08 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jan 2026, 06:15:20 UTC
Prior SEC filing: 04 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Malte Peters filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 12 Jan 2026.

Key facts

This page summarizes Malte Peters's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jan 2026, 06:15.

Change

Previous filing in this sequence was filed on 04 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001876563 Primary reporting owner

Peters Malte

Relationship: President & CEO, Director
Address: C/O TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 12 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Award

Transaction value: $0
Shares: +350,000
Change %: +2000%
Price: $0.000000
Shares after: 367,500
Date: 08 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +1,650,000
Change %
Price: $0.000000
Shares after: 1,650,000
Date: 08 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,650,000
Exercise price: $11.06
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Footnote F2

This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.